Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
This article was originally published in The Pink Sheet Daily
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
You may also be interested in...
HONG KONG - China's pharmaceutical market is expected to grow around 26% in the coming year with much of the growth fueled by continued implementation of the government's Essential Drug List (EDL) and reimbursement expansion via government insurance plans, said Katherine Lu, senior analyst for China healthcare at Oppenheimer & Co
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
SHANGHAI - GlaxoSmithKline announced that the company has reached an agreement to acquire urology-dedicated Nanjing MeiRui in China for $70 million to expand its urology and over-the-counter presence in China's booming pharmaceutical market